Arsanis’ (NASDAQ:ASNS) quiet period is set to expire on Tuesday, December 26th. Arsanis had issued 4,000,000 shares in its public offering on November 16th. The total size of the offering was $40,000,000 based on an initial share price of $10.00. During Arsanis’ quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

A number of equities analysts have recently weighed in on ASNS shares. Piper Jaffray Companies started coverage on Arsanis in a research note on Monday, December 11th. They set an “overweight” rating and a $23.00 target price on the stock. Cowen started coverage on Arsanis in a research note on Monday, December 11th. They set an “outperform” rating on the stock. Finally, Citigroup started coverage on Arsanis in a research note on Monday, December 11th. They set a “buy” rating and a $27.00 target price on the stock.

Arsanis (ASNS) opened at $12.47 on Tuesday. Arsanis has a 52 week low of $10.40 and a 52 week high of $19.73.

In related news, Director Tillman U. Gerngross purchased 200,000 shares of Arsanis stock in a transaction that occurred on Monday, November 20th. The shares were acquired at an average price of $10.00 per share, with a total value of $2,000,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Polaris Venture Management Co. purchased 500,000 shares of Arsanis stock in a transaction that occurred on Monday, November 20th. The shares were bought at an average cost of $10.00 per share, for a total transaction of $5,000,000.00. The disclosure for this purchase can be found here.

TRADEMARK VIOLATION WARNING: “Arsanis, Inc.’s Quiet Period Will Expire on December 26th (NASDAQ:ASNS)” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/arsanis-inc-s-quiet-period-will-expire-on-december-26th-nasdaqasns/1772003.html.

Arsanis Company Profile

Arsanis, Inc is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company’s mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500.

Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.